BridgeMD
New treatment option for Drug Resistant Epilepsy
Official title Biomarkers of Response to SEEG Thermocoagulation
ClinicalTrials.gov ID: NCT07399327
What this study is testing
- What it's testing
- Drug-resistant focal epilepsy is a severe neurological disease that affects one-third of patients with epilepsy. Surgery is the only potentially curative treatment.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 12 and older
You may be able to join if
- Patient, parents or legal representative who have given their written informed consent,
- Adult or pediatric patient ≥ 12 years old suffering from drug-resistant focal epilepsy,
- Standardized pre-surgical assessment including medical history, scalp video-EEG and 3T MRI,
- Patients in whom a SEEG exploration for pre-surgical evaluation has been indicated,
- Patient able to understand, speak and write in French,
You likely can't join if
- Epilepsy surgery performed without the requirement of SEEG,
- Contraindication to 3T or 7T brain MRI (patient with a cardiac pacemaker, metallic foreign bodies, non-removable implanted electronic medical...
- Contraindication to gadolinium-based MRI contrast agent (history of allergic or anaphylactic reaction to gadolinium, hypersensitivity to gadoteric...
- Person protected by articles L1121-5, L1121-6 and L1121-8 of the Public Health Code (pregnant or breastfeeding woman, deprived of liberty by judicial...
- Patient in exclusion period of another study.
See the full eligibility criteria
- Patient, parents or legal representative who have given their written informed consent,
- Adult or pediatric patient ≥ 12 years old suffering from drug-resistant focal epilepsy,
- Standardized pre-surgical assessment including medical history, scalp video-EEG and 3T MRI,
- Patients in whom a SEEG exploration for pre-surgical evaluation has been indicated,
- Patient able to understand, speak and write in French,
- Patient able to follow study's procedure,
- Patient beneficiary or affiliated to a health insurance plan.
- Epilepsy surgery performed without the requirement of SEEG,
- Contraindication to 3T or 7T brain MRI (patient with a cardiac pacemaker, metallic foreign bodies, non-removable implanted electronic medical devices, claustrophobia, inability to remain in supine position, patient...
- Contraindication to gadolinium-based MRI contrast agent (history of allergic or anaphylactic reaction to gadolinium, hypersensitivity to gadoteric acid, meglumine, or any drug containing gadolinium, severe renal failure...
- Person protected by articles L1121-5, L1121-6 and L1121-8 of the Public Health Code (pregnant or breastfeeding woman, deprived of liberty by judicial decision, situations of social fragility, adults unable or unable to...
- Patient in exclusion period of another study.
The study team makes the final eligibility decision.
Where it's taking place
- Marseille, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 12 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Marseille, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.